Trupanion stock price target raised to $67 at BofA on earnings beat

Trupanion (NASDAQ:TRUP) reported robust Q2 2025 results, with EPS of $0.22 significantly exceeding consensus and analyst forecasts, primarily boosted by a $7.8 million one-time gain from preferred stock. Revenue reached $354 million, surpassing management's guidance and consensus, while subscription pet count grew 4% year-over-year. In response, BofA Securities raised its price target on TRUP to $67.00 from $56.00, maintaining a Buy rating, signaling positive analyst sentiment despite the non-recurring nature of the earnings beat's key driver.

Analysis

Trupanion (TRUP) reported a significant second-quarter 2025 earnings beat, with an EPS of $0.22 surpassing the consensus forecast of a $0.04 loss per share. However, this outperformance was primarily driven by a one-time, non-operational gain of $7.8 million from an exchange of preferred stock for intellectual property, a factor that warrants careful consideration when assessing underlying profitability. Alongside this, BofA Securities raised its price target to $67.00 from $56.00, maintaining a Buy rating. The company's revenue of approximately $354 million exceeded its own guidance but fell short of BofA's $361 million forecast, suggesting a mixed top-line result. Core operational metrics were stable, with the subscription pet count growing 4% year-over-year, in line with expectations. The medical loss ratio of 71.1% was also favorable, although it was aided by 60 basis points of positive prior-year development, slightly flattering the quarterly performance.

Key Decisions for Investors

• Investors should look past the headline EPS beat and scrutinize the company's underlying operational profitability, as the positive result was substantially influenced by a one-time, non-recurring gain.
• Monitor core growth metrics, particularly subscription pet count and the medical loss ratio excluding prior-period adjustments, as these are more reliable indicators of the company's sustainable long-term performance.
• While BofA's price target increase to $67.00 suggests significant upside from the current price, caution is warranted given that revenue missed the analyst's forecast, indicating potential challenges to achieving that valuation through organic growth alone.